Phase 2 trial of single-agent gemcitabine in platinum-paclitaxel refractory ovarian cancer

By Markman M.   Webster K.   Zanotti K.   Kulp B.   Peterson G.   Belinson J.  

Gynecologic Oncology, Vol. 90, Iss. 3, 2003-09 ,pp. : 593-596

Elsevier

Access to resources Recommend Favorite

Phase 2 Trial of Moderately High Dose Single Agent Mitoxantrone in Platinum and Paclitaxel-Refractory Ovarian Cancer

By Markman M.   Lichtman S.M.   Homesley H.   Kennedy A.   Webster K.   Ernst S.   Omura G.   Belinson J.  

Gynecologic Oncology, Vol. 70, Iss. 1, 1998-07 ,pp. : 123-126

Elsevier

Access to resources Recommend Favorite

Phase 2 trial of single agent docetaxel in platinum and paclitaxel-refractory ovarian cancer, fallopian tube cancer, and primary carcinoma of the peritoneum

By Markman M.   Zanotti K.   Webster K.   Peterson G.   Kulp B.   Belinson J.  

Gynecologic Oncology, Vol. 91, Iss. 3, 2003-12 ,pp. : 573-576

Elsevier

Access to resources Recommend Favorite

Randomized Trial of Single Agent Paclitaxel Given Weekly Versus Every Three Weeks and with Peroral Versus Intravenous Steroid Premedication to Patients with Ovarian Cancer Previously Treated with Platinum

By Rosenberg Per   Andersson Ha˚kan   Boman Karin   Ridderheim Mona   Sorbe Bengt   Puistola Ulla   Parö Gunnar  

Acta Oncologica, Vol. 41, Iss. 5, 2002-09 ,pp. : 418-424

Informa Healthcare

Access to resources Recommend Favorite

Ifosfamide/Mesna as Salvage Therapy in Platinum Pretreated Ovarian Cancer Patients—Long-Term Results of a Phase II Study

By Baur Martina   Fazeny-Doerner B.   Hudec M.   Sevelda P.   Salzer H.   Dittrich Christian  

Cancer Investigation, Vol. 24, Iss. 1, 2006-03 ,pp. : 22-27

Informa Healthcare

Access to resources Recommend Favorite